ZURICH, Nov 27 (Reuters) - Idorsia plans to restructure

its debt, implement cost-cutting measures and could shed up to

270 jobs in a bid to spur profitability, the Swiss pharma

company said on Wednesday.

Idorsia, which posted a net loss of 180 million Swiss francs

($203 million) for the first nine months of 2024, said it aims

to conclude the restructuring by the end of the year, with the

cost reductions fully effective by the second quarter of 2025.

The shake-up plan includes steps to restructure the

company's outstanding debt, CEO Andre Muller said.

"I am confident that our plan is achievable within the next

few months, and that will allow us to shift our focus back to

our products," he said.

To reach sustainable profitability, the company said it must

focus efforts, reducing the number of active projects in

research and development and preparing some for out-licensing.

To this end, it plans to cut staffing levels and said that

depending on the outcome of a consultation process, about 270

positions globally could become redundant, mainly in research

and development and support functions at headquarters.

According to its website, the company has over 750

employees.

Idorsia also said it had entered into negotiations with an

undisclosed party over the global rights to its medication

aprocitentan, which is used to treat high blood pressure.

Idorsia will receive an exclusivity fee of $35 million,

the firm said.

($1 = 0.8854 Swiss francs)

(Writing by Dave Graham; editing by Miranda Murray and Jason

Neely)